These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 9811779)
1. In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T J Virol; 1998 Dec; 72(12):10298-300. PubMed ID: 9811779 [TBL] [Abstract][Full Text] [Related]
2. Generation and neutralization of pseudovirions of human papillomavirus type 33. Unckell F; Streeck RE; Sapp M J Virol; 1997 Apr; 71(4):2934-9. PubMed ID: 9060652 [TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. Kawana Y; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T J Virol; 2001 Mar; 75(5):2331-6. PubMed ID: 11160736 [TBL] [Abstract][Full Text] [Related]
4. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405 [TBL] [Abstract][Full Text] [Related]
5. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T J Virol; 1999 Jul; 73(7):6188-90. PubMed ID: 10364381 [TBL] [Abstract][Full Text] [Related]
6. Infectious human papillomavirus type 18 pseudovirions. Stauffer Y; Raj K; Masternak K; Beard P J Mol Biol; 1998 Oct; 283(3):529-36. PubMed ID: 9784363 [TBL] [Abstract][Full Text] [Related]
7. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909 [TBL] [Abstract][Full Text] [Related]
8. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673 [TBL] [Abstract][Full Text] [Related]
9. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. Roden RB; Greenstone HL; Kirnbauer R; Booy FP; Jessie J; Lowy DR; Schiller JT J Virol; 1996 Sep; 70(9):5875-83. PubMed ID: 8709207 [TBL] [Abstract][Full Text] [Related]
10. Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16. El Mehdaoui S; Touzé A; Laurent S; Sizaret PY; Rasschaert D; Coursaget P J Virol; 2000 Nov; 74(22):10332-40. PubMed ID: 11044077 [TBL] [Abstract][Full Text] [Related]
11. In vitro gene transfer using human papillomavirus-like particles. Touze A; Coursaget P Nucleic Acids Res; 1998 Mar; 26(5):1317-23. PubMed ID: 9469843 [TBL] [Abstract][Full Text] [Related]
12. Infectious virions produced from a human papillomavirus type 18/16 genomic DNA chimera. Meyers C; Bromberg-White JL; Zhang J; Kaupas ME; Bryan JT; Lowe RS; Jansen KU J Virol; 2002 May; 76(10):4723-33. PubMed ID: 11967289 [TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Heino P; Dillner J; Schwartz S Virology; 1995 Dec; 214(2):349-59. PubMed ID: 8553535 [TBL] [Abstract][Full Text] [Related]
14. [Establishment and application of human papillomavirus type 16 pseudovirions neutralization assay]. Lu WX; Cheng T; Li SW; Pan HR; Shen WT; Chen YX; Zhang T; Zheng Z; Zhang J; Xia NS Sheng Wu Gong Cheng Xue Bao; 2006 Nov; 22(6):990-5. PubMed ID: 17168325 [TBL] [Abstract][Full Text] [Related]
15. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. Kirnbauer R; Taub J; Greenstone H; Roden R; Dürst M; Gissmann L; Lowy DR; Schiller JT J Virol; 1993 Dec; 67(12):6929-36. PubMed ID: 8230414 [TBL] [Abstract][Full Text] [Related]
16. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908 [TBL] [Abstract][Full Text] [Related]
17. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
18. Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. McCarthy MP; White WI; Palmer-Hill F; Koenig S; Suzich JA J Virol; 1998 Jan; 72(1):32-41. PubMed ID: 9420197 [TBL] [Abstract][Full Text] [Related]
19. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. Rose RC; Bonnez W; Reichman RC; Garcea RL J Virol; 1993 Apr; 67(4):1936-44. PubMed ID: 8383219 [TBL] [Abstract][Full Text] [Related]
20. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. Touze A; El Mehdaoui S; Sizaret PY; Mougin C; Muñoz N; Coursaget P J Clin Microbiol; 1998 Jul; 36(7):2046-51. PubMed ID: 9650960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]